SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Beryl Drugs Ltd

BSE: 524606 NSE: ISIN: INE415H01017
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Beryl Drugs Ltd belong to?
Beryl Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Beryl Drugs Ltd a good quality company?
Beryl Drugs Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Beryl Drugs Ltd undervalued or overvalued?
Beryl Drugs Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Beryl Drugs Ltd a good buy now?
Beryl Drugs Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Beryl Drugs Ltd?
Beryl Drugs Ltd revenue growth is -20.9% for FY-2025 , which is below its 5 year CAGR of 10.5% , indicating slower growth.
Q.2 Gross Profit margin of Beryl Drugs Ltd?
Beryl Drugs Ltd Gross profit margin which is the profit after deduction of direct costs, is 10% for FY-2025 , which is above its 5 year median of 8.3% , indicating increasing margins.
Q.3 Operating Profit Margin of Beryl Drugs Ltd?
Beryl Drugs Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 4.73% for FY-2025 , which is below its 5 year median of 7.39% indicating decreasing margins.
Q.4 Net Profit Margin of Beryl Drugs Ltd?
Beryl Drugs Ltd Net Profit Margin is 2.74% for FY-2025 , is in line with with its 5 year median of 2.74%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 10 8.3
Operating Profit Margin 4.73 7.39
Net Profit Margin 2.74 2.74
Q.5 Return on Asset of Beryl Drugs Ltd?
Beryl Drugs Ltd Return on Asset is 3.43%, which is in line with its 5 year historical median of 3.43%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Beryl Drugs Ltd?
Beryl Drugs Ltd Return on equity is 6.3% for FY-2025 , which is in line with its historical median of 6.3%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Beryl Drugs Ltd?
Beryl Drugs Ltd Return on capital employed is 10.15% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Beryl Drugs Ltd?
Beryl Drugs Ltd Cash conversion cycle is 112 days, above its historical median of 93 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.25 1.25
ROE 6.3 6.3
ROCE 10.15 10.15
Cash Conversion Cycle 112 days 93 days
Q.9 Debt to Equity ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd Debt-to-Equity ratio is 0.43 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Beryl Drugs Ltd?
Beryl Drugs Ltd Debt to cash flow from operations is 1.55 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Beryl Drugs Ltd?
Promoters hold 27.48% of the Beryl Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Beryl Drugs Ltd vs industry peers?
Beryl Drugs Ltd revenue CAGR is 10.53% , compared to the industry median CAGR of 5.51% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 21.2 138.8
Gross Profit 2.1 16.2
Operating Profit 1 16
Net Profit 0.6 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.25 0.79
ROE 6.3 9.17
ROCE 10.15 11.78
Cash Conversion Cycle (days) 112.41 76

Valuation & price assessment

Q.1 Stock return of Beryl Drugs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -3.5% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -3.5% 33% 20.9% -1.5%
Q.3 Valuation ratios of Beryl Drugs Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 918.76 15.04 40.28
Price to Book 1.29 1.07 2.77
Price to Sales 0.68 0.40 2.65
EV to EBITDA 10.23 7.74 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Sai Life Sciences
8. Astrazeneca Pharma I
9. Piramal Pharma
10. Acutaas Chemicals
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×